))
A Discussion with Jeb Besser, Managing Member at Manchester Management & CEO of Modular Medical
Manage episode 337249287 series 3380517
Innehåll tillhandahållet av Encode Ideas, L.P., Encode Ideas, and L.P.. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Encode Ideas, L.P., Encode Ideas, and L.P. eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
An interview with Jeb Besser, Managing Member at Manchester Management, a $100M AUM hedge fund that makes concentrated investments in micro/small cap health care and technology companies. In February 2022, Jeb also stepped into the CEO role at Modular Medical, a development-stage insulin pump company, where Manchester is the largest shareholder. During the interview, Jeb outlines his enthusiasm for Modular and why the timing was right for him to assume the CEO role. He also discusses two other of Manchester's favorite health care holdings in Fennec Pharmaceuticals and Alpha Cognition.
Companies discussed during the podcast;
- Modular Medical Inc. (Nasdaq: MODD)
- Fennec Pharmaceuticals Inc. (Nasdaq: FENC, TSX: FRX)
- Alpha Cognition Inc (OTC: ACOGF, TSX-V: ACOG)
- Tandem Diabetes Care Inc. (Nasdaq: TNDM)
- Insulet Corporation (Nasdaq: PODD)
- Medtronic plc (NYSE: MDT)
- Biogen Inc (Nasdaq: BIIB)
- Cassava Sciences Inc (Nasdaq: SAVA)
James (Jeb) Besser, who is an executive of Modular Medical, Inc. (“Modular”) appeared on this episode of the podcast. Listeners are urged to review Modular’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Modular undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
Disclaimer:
This podcast does not contain financial advice and is for entertainment purposes only. Comments made in the podcast should not be considered an inducement to buy or sell any securities.
7 episoder
Dela
